Trial reportBMC infectious diseases2026
A bidimensional early intervention strategy of standard of care in combination with corticosteroids in elderly patients with mild to moderate COVID-19 (BEAT-COV study): a multicentre, open-label, randomized controlled trial.
Trial report in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05855395 (A Bidimensional Early Intervention Strategy of Standard of Care Combined With Host Immunomodulation in Elderly Patients With Mild or Moderate COVID-19), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Bidimensional Early Intervention Strategy of Standard of Care Combined With Host Immunomodulation in Elderly Patients With Mild or Moderate COVID-19: A Multicentre, Randomized, Controlled, Adaptive Platform Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundElderly adults are at high risk for severe coronavirus disease 2019 (COVID-19). Whether the use of corticosteroids in this population with mild to moderate COVID-19 could prevent disease progression remains controversial.
methodsThe BEAT COV trial assessed corticosteroids treatments in elderly patients with mild to moderate COVID-19. Eligible patients were randomly allocated (1:1) to either the intervention group (oral corticosteroids in combination with standard of care (SOC)) or the control group (SOC alone). Non-randomized patients were enrolled in an observational cohort. The primary outcome was the rate of severe or critical COVID-19 within 28 days.
resultsThe study was terminated prematurely due to low COVID-19 prevalence and decreasing severe cases, leading to an underpowered sample size. A total of 344 patients were screened, 193 patients were randomly allocated to receive corticosteroids in combination with SOC (95 patients) versus SOC alone (98 patients), 151 patients were included in the observational cohort. In the full analysis set (FAS) population, 1 (1.09%) patient in the corticosteroid group and 4 (4.17%) patients in the SOC group developed severe or critical COVID-19 within 28 days (relative risk 0.26 [95% confidence interval {CI} 0.03–2.29]; p = 0.3688). Similar findings were observed in the per-protocol (PP) population. One (0.75%) patient in the observational cohort developed severe COVID-19 within 28 days. All the adverse drug reactions (ADRs) were mild.
conclusionsIn elderly with non-severe COVID-19, the use of corticosteroids combined with SOC did not significantly reduce the incidence of severe or critical COVID-19 compared to SOC alone. And the treatment shows a favorable safety profile. The study is exploratory in nature due to insufficient power, and given the limited evidence, further studies with larger sample sizes are warranted.
trial registrationClinicalTrials.gov identifier, NCT05855395, registered on [2023-05-11] (https://clinicaltrials.gov/ct2/show/NCT05855395)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.